Seroquel Prolong (quetiapine)
Seroquel Prolong (quetiapine) is an oral slow-release formulation, which – in contrast to normal quetiapine-tablets - should be dosed once a day, in stead of two.
Effect in treatment of schizophrenic patients is presumably comparable with the effect of normal quetiapine tablets. However, a "not poorer" (non-inferior) effect of the depot tablets compared to the normal tablets, has only been showed in a per-protocol-analysis in a 6 week non-inferiority study, and not in the full-analysis set of patients that also included non compliant patients (intention-to-treat). Practically therefore, doctors has to judge the individual patient as to whether
he og she will need a higher dose of the slow-release formulation, than normally, to assure a stable treatment.
Side effects are not fewer nor more that with the normal quetiapine tablets.
One daily dose of Seroquel Prolong (600 mg) costs 66.30 Dkr. This is at the same level as normal quatiapin-tablets, but up to 96 times more expensive than the generic risperidone, that costs 0,69 Dkr. for one equivalent daily dose of 4 mg (doses according to the National Recommendation list).
IRF states, that Seroquel Prolong is a very expensive treatment, that only should be used, in cases where other antipsychotic treatment (risperidone, amisulpride) has been tried, and the once-a-day regime is necessary. If dose adjustments compared to normal-release tablets are necessary, it should be noted that the price - in spite of the intention – can become higher than the price of normal quetiapine tablets.
Seroquel Prolong is approved as an antipsychotic drug the 7th of April 2008 and has – so far – the same indications as Seroquel.
Seroquel Prolong is under the rules of general reimbursement.